TEDA Biomedical (8189) Issues Supplemental Disclosure for 2019 Annual Report

Bulletin Express

Oct 22, 2025

TEDA Biomedical (8189) published a supplemental announcement regarding its 2019 Annual Report, originally released on 28 April 2020. The announcement clarifies compensation details for former CEO Yang Junmin during his tenure from 1 February 2019 to 30 December 2019.

According to the supplemental information, Yang’s salary and other benefits totaled RMB626,569, while his retirement benefits scheme contributions amounted to RMB107,255. The combined emoluments reached RMB733,824. The announcement, dated 22 October 2025, reaffirms this figure and was issued by Chairman Sun Li on behalf of the board of directors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1153854964"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153854964\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153854964?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153854964","market":"us","top_or_hot":-1,"title":"TEDA Biomedical (8189) Issues Supplemental Disclosure for 2019 Annual Report","media":"Bulletin Express","content":"<p>TEDA Biomedical (8189) published a supplemental announcement regarding its 2019 Annual Report, originally released on 28 April 2020. The announcement clarifies compensation details for former CEO Yang Junmin during his tenure from 1 February 2019 to 30 December 2019.</p>\n<p>According to the supplemental information, Yang’s salary and other benefits totaled RMB626,569, while his retirement benefits scheme contributions amounted to RMB107,255. The combined emoluments reached RMB733,824. The announcement, dated 22 October 2025, reaffirms this figure and was issued by Chairman Sun Li on behalf of the board of directors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TEDA Biomedical (8189) Issues Supplemental Disclosure for 2019 Annual Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTEDA Biomedical (8189) Issues Supplemental Disclosure for 2019 Annual Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-22 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TEDA Biomedical (8189) published a supplemental announcement regarding its 2019 Annual Report, originally released on 28 April 2020. The announcement clarifies compensation details for former CEO Yang Junmin during his tenure from 1 February 2019 to 30 December 2019.</p>\n<p>According to the supplemental information, Yang’s salary and other benefits totaled RMB626,569, while his retirement benefits scheme contributions amounted to RMB107,255. The combined emoluments reached RMB733,824. The announcement, dated 22 October 2025, reaffirms this figure and was issued by Chairman Sun Li on behalf of the board of directors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08189","symbol_name":"泰达生物","start_time":0,"source_url":"","article_id":"1153854964","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153854964","pubTimestamp":1761133425,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TEDA Biomedical (8189) published a supplemental announcement regarding its 2019 Annual Report, originally released on 28 April 2020. The announcement clarifies compensation details for former CEO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08189":"泰达生物"},"translate_title":"泰达生物医药(8189)发布2019年年报补充披露","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08189":1},"content_text":"TEDA Biomedical (8189) published a supplemental announcement regarding its 2019 Annual Report, originally released on 28 April 2020. The announcement clarifies compensation details for former CEO Yang Junmin during his tenure from 1 February 2019 to 30 December 2019.\nAccording to the supplemental information, Yang’s salary and other benefits totaled RMB626,569, while his retirement benefits scheme contributions amounted to RMB107,255. The combined emoluments reached RMB733,824. The announcement, dated 22 October 2025, reaffirms this figure and was issued by Chairman Sun Li on behalf of the board of directors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}